Pascual-Mathey Luz I, Velez-Figueroa Midory I, Díaz-Vallejo Joel J, Mendez-Hirata Gustavo, Mendez-Machado Gustavo F
Laboratory of Molecular Biology, Faculty of Pharmaceutical Biological Chemistry, Veracruzana University, Jalapa 91190, Mexico.
UMAE Specialty Hospital 14, National Medical Center Adolfo Ruiz Cortines, IMSS, Veracruz 91810, Mexico.
Reports (MDPI). 2024 Sep 14;7(3):76. doi: 10.3390/reports7030076.
In Mexico, breast cancer (BC) is the principal cause of death in women over 30 years old, with an annual mortality rate of 14.61 deaths per a 100,000 population. Chemotherapy, in combination with trastuzumab (TTZ), improves the survival of cancer patients; however, cardiotoxicity (CT) is the principal consequence. CT prevalence occurs between 10% and 30% of patients; however, there are no data about the prevalence of CT in the Mexican population. This study aims to establish the prevalence of CT in patients treated with anti-HER-2 therapy among BC women in southeast Mexico. A retrospective cross-sectional study was carried out from January 2015 to July 2019. The records of 46 patients diagnosed with HER-2-positive BC who attended the Mexican Social Security Institute in the Ambulatory Care Medicine Unit were analyzed. The diagnostic criterion for CT was a decrease in LVEF > 10% from baseline or a final LVEF < 53%. CT prevalence was observed in 19 (41.3%) of women with cancer, with an average decrease in LVEF of 13%. In the population, we found an association between weight, surface area, and the loading dose of TTZ with CT. Nutritional follow-up and the administration of cardioprotective drugs are necessary to recover LVEF and avoid cardiovascular failure in women with BC and survivors.
在墨西哥，乳腺癌是30岁以上女性的主要死因，年死亡率为每10万人口中有14.61人死亡。化疗联合曲妥珠单抗（TTZ）可提高癌症患者的生存率；然而，心脏毒性（CT）是主要后果。CT在10%至30%的患者中出现；然而，墨西哥人群中关于CT患病率的数据尚无。本研究旨在确定墨西哥东南部乳腺癌女性中接受抗HER-2治疗患者的CT患病率。于2015年1月至2019年7月进行了一项回顾性横断面研究。分析了46例在墨西哥社会保障机构门诊医疗科就诊的诊断为HER-2阳性乳腺癌患者的记录。CT的诊断标准是左心室射血分数（LVEF）较基线下降>10%或最终LVEF<53%。在19名（41.3%）癌症女性中观察到CT患病率，LVEF平均下降13%。在该人群中，我们发现体重、体表面积和TTZ负荷剂量与CT之间存在关联。营养随访和给予心脏保护药物对于恢复BC女性及其幸存者的LVEF和避免心血管衰竭是必要的。
